IBB News and Press, iShares Biotechnology ETF From 03/10/24

2024-03-10 12:09:40 ET Summary Private sector recorded a surplus of $319B in February 2024, leading to growth in asset markets. Federal government injected $309B into the private sector, while $67B flowed out to foreign bank accounts. Fiscal impulse is rising, pointing to a po...

2024-03-09 03:59:00 ET Summary Jared Ablass, Vice President, Portfolio Research at TD Asset Management, speaks with Greg Bonnell about how the biotech sector could benefit once rates start to come down. Why beaten down Biotech stocks could be ready for a healthy recovery. Biot...

2024-03-06 11:25:10 ET Over the past 3 months the biotech space is +30.4% and has only been outperformed by semiconductors, computer processing hardware and the computer peripherals industries. Additionally, the biotech sector is +13.6% in 2024, outdoing all of the major market aver...

2024-02-23 04:05:00 ET Summary Within healthcare, an area that has been negatively impacted the last couple of years is the pharmaceutical manufacturing value chain. Several capital goods and materials sectors experienced recessionary conditions last year, which caused weak fundam...

2024-02-19 15:48:49 ET More on iShares Biotechnology ETF, iShares U.S. Medical Devices ETF, etc. XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance THQ Vs. XBI: Keeping The Biotech ETF For Now XBI: Biotech Speculation Top 10 ETFs...

2024-02-15 16:42:56 ET More on iShares Biotechnology ETF, SPDR S&P Biotech ETF, etc. THQ Vs. XBI: Keeping The Biotech ETF For Now XBI: Biotech Speculation Healthcare In 2024: Navigating The Biopharma Bull Run Biogen, Neurocrine, and more are Bairds top pi...

2024-02-10 09:03:50 ET Summary Joe Biden's student debt relief may help rectify his previous support for stricter bankruptcy laws on student debt. The US sectoral flows for January 2024 indicate a negative result for asset markets. The stock market is predicted to finish Febru...

2024-02-07 01:53:00 ET Summary A sub-$3trn 2023 for M&A, but new year pipeline gives hope. Rising follow-on equity in 2023 signals latent appetite. Unstoppable debt capital markets hit $8.9trn for FY2023. By Lucille Jones, Senior Manager, Deals Intelligence and...

2024-01-31 04:36:00 ET Summary 2023 was characterized by narrow leadership and multiple expansions. While last year’s gains have led to headline valuations appearing stretched, there are many segments of the market that are not as aggressively priced. With the expectati...

2024-01-17 23:22:58 ET Summary The healthcare sector presents a unique investment opportunity in 2024 due to attractive valuation and uncorrelated/robust cashflow of healthcare. Biopharma companies have pricing power and ability to adjust drug prices in line with inflation, provid...